Wells Fargo upgraded Relay Therapeutics (RLAY) to Overweight from Equal Weight with a price target of $13, up from $6. The firm believes the stock could work in 2026 on its data updates. Wells expects the RLY-2608 data to be competitive.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY: